Choroideremia Drug Pipeline Insights Report 2022 Featuring Spark Therapeutics, Molecular Therapeutics, Curative Biotechnology, & Ray Therapeutics - ResearchAndMarkets.com
2022-11-16
临床1期基因疗法
DUBLIN--(BUSINESS WIRE)--The "Choroideremia - Pipeline Insight, 2022" report has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Choroideremia pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Choroideremia pipeline landscape is provided which includes the disease overview and Choroideremia treatment guidelines. The assessment part of the report embraces, in depth Choroideremia commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Choroideremia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence R&D Choroideremia. The therapies under development are focused on novel approaches to treat/improve Choroideremia.
In February 2019, Roche entered into a definitive merger agreement to acquire Spark Therapeutics and its clinical assets, including SPK-7001 for choroideremia in Phase I/II.
4D therapeutics is developing and investigating its lead product candidate 4D-110 in an ongoing Phase I dose-escalation clinical trial in patients with choroideremia related to mutations in the CHM gene.
Choroideremia Emerging Drugs
AAV2-hCHM: Spark Therapeutics
Spark Therapeutics is advancing an open-label, dose-escalating Phase I/II trial designed to assess the safety and preliminary efficacy of subretinal administration of investigational SPK-7001. Each of the investigational research programs uses an adeno-associated viral (AAV) vector developed and manufactured by the Spark team and their collaborators.
Choroideremia: Therapeutic Assessment
This segment of the report provides insights about the Choroideremia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Choroideremia
There are approx. 5+ key companies which are developing the therapies Choroideremia. The companies which have their Choroideremia drug candidates in the most advanced stage, i.e phase I/II include Spark Therapeutics
Phases
This report covers around 5+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Choroideremia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
Small molecule
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Choroideremia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Choroideremia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Choroideremia drugs.
Choroideremia Report Insights
Choroideremia Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Choroideremia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Choroideremia drugs?
How many Choroideremia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Choroideremia and their status?
What are the key designations that have been granted to the emerging drugs?
Key Products
4D 110
Metformin
RAY 001
For more information about this report visit https://www.researchandmarkets.com/r/suln3y
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。